

UK Patent Application

(12) (19) GB (11) 2 200 651 (13) A
(43) Application published 10 Aug 1988

(21) Application No 8800696.

(22) Date of filing 13 Jan 1988

(30) Priority data

(31) 8702816

(32) 7 Feb 1987

(33) GB

(71) Applicant

Ayad Mohamed Khalaf Al-Sumidale
68 St. Ives Way, Halewood, Liverpool, L26 7YW

(72) Inventor

Ayad Mohamed Khalaf Al-Sumidale

(74) Agent and/or Address for Service

Roystons
Tower Building, Water Street, Liverpool, L3 1BA

(51) INT CL⁴
C12N 7/00

(52) Domestic classification (Edition J):
C6F 10X J
G1B BV
U1S 1313 C6F G1B

(56) Documents cited
Oncology (Basel) (1982) Vol 39(5) p 304-7
Conference Advances Comp Leuk Res Proc
Int Symp 9th (80) p87-8 \equiv Chem Abs. Vol 93 (21)198232
Br. J. Cancer (1983) p683-8 Vol 48 No. 5 \equiv Chem Abs
Vol 100 (05) 30020
J. Nation Cancer Inst. (1978) Vol 60(6) p 1305-8
J. Immunol. (1983) Vol 131 (5) p2279-81

(58) Field of search

C6F
Selected US specifications from IPC sub-class
C12N

(54) A method of obtaining a retrovirus-containing fraction from retrovirus-containing cells

(57) The present invention relates to a method of obtaining a retrovirus-containing fraction, and in particular, though not exclusively, to obtaining a retrovirus containing fraction from mononuclear cells containing a retrovirus.

The method of forming a retrovirus-containing fraction from mononuclear cells containing said virus comprises, preparing a suspension of separated mononuclear cells in a culture medium, incubating said culture, and separating the culture supernatant from said incubated culture, characterized in that an effective amount of a glucocorticoid or of a leukemia or viral inducing drug is added to the suspension before and/or during the incubation of said cultures, and if desired separating a retrovirus containing fraction from the separated supernatant.

Title: A method of obtaining a retrovirus-containing fraction from retrovirus-containing cells

DESCRIPTION

5 The present invention relates to a method of obtaining a retrovirus-containing fraction, and in particular, though not exclusively, to obtaining a retrovirus-containing fraction from mononuclear cells containing a retrovirus. The use of such a method 10 providing means for screening said cells for the presence of said retrovirus and also an isolated fraction enabling positive identification of the particular virus to be achieved.

It has long been suspected that cancer, and in particular, breast cancer may be a result of viral infection. In females the most common form of malignancy is carcinoma of the breast. This carcinoma is known to affect about 9 per cent of the adult female population and in females in the 40 to 54 age group is 20 a major cause of death. A problem in diagnosis is that in many of these carcinomas the cancerous growth

is slow, possibly taking up to 10 years for a 1 cm growth, and as a result of this slow growth, many carcinomas are not detected until the carcinoma is too advanced.

5 Whilst early diagnosis of such cancers materially enhances the possibility of a cure it is evident that detection of the causal factor before the cancer becomes manifest would enable prevention measures to be developed. Thus providing a screening method to enable 10 early and effective recognition of the presence of the causal factor would increase greatly the possibility of successfully treating many patients.

There is also no method of identifying an effective treatment for a patient with breast cancer. 15 Different treatments may be tried and continued depending on the patient's response. But there is no blood test for monitoring the continuous effect of a treatment on the retrovirus present in mononuclear or monocytes from patients with breast cancer.

20 At present there is no method which can be used in screening for breast cancer in the very early stages and no method by which retroviruses are screened for directly, although it is known to screen for retroviruses indirectly by use of a mouse mammary tumor 25 antibody, but because of the possibility of

cross-reactivity that indirect method can give false positive results.

It is also known to screen for retroviruses by assaying for the enzyme reverse transcriptase. To do this the virus must undergo replication to provide enough reverse transcriptase to allow positive identification.

It is known that in genetically susceptible mice a virus, Murine mammary tumor virus, MMTV, can be the cause of breast cancers, the virus being detectable in the mammary tumor cells of the infected mice.

It is further known that virus particles of type C morphology can be enhanced in mammary tumor cells of mice by the use of adrenocorticoids. The use of these hormones results in increased production of virus related RNA-dependent DNA polymerase, MMTV specific antigens, and B particles. This was shown when the synthetic glucocorticoid hormone, dexamethasone, was used in cultures of iododeoxyuridine (IUDR) stimulated mouse mammary tumour cells. In these experiments dexamethasone was added to the growth medium after IUDR treatment, IUDR being known to act as an inducer of leukemia and herpes viruses. (Fine et al. June 1974, Journal of the National Cancer Institute 52, 6, pages 1881-1884). Furthermore, in cell lines and primary

explants derived from mammary tumours of several strains of mice the amount of virus production correlates with the level of virus-specific RNA. This suggests that in these cells, transcriptional controls are of primary importance in regulating the production of MMTV. Experiments with dexamethasone (a synthetic glucocorticoid) support this notion since cells treated with the hormone show parallel increases in virus production and intracellular virus-specific RNA. In contrast, a lymphoma cell line (S49) derived from a lymphoma induced by mineral oil in a BALB/c mouse contains large quantities of MMTV-specific RNA yet produces extremely low levels of virus. In these cells, mechanisms other than transcriptional controls may be important in regulating virus production. (Ringold 1975, Virology 65, pages 135-147).

However, MMTV differs in several respects from other members of the retrovirus family. For example it induces a high incidence of mammary adenocarcinomas as opposed to the more common leukemias and sarcomas associated with other retroviruses. (Dickson 1981, Journal of Virology January, 37 pages 36-47).

It is known that blood leukocytes including monocytes are attracted to diseased regions of the body in response to chemotactic agents. (Al-Sumidaie et al.

1984, Journal of Immunological Methods 75, pages 129-140). The leukocytes are believed to become involved in elimination and destruction of tumour cells. However it has surprisingly been shown that 5 monocytes, from patients with breast carcinoma when incubated in vitro using an under agarose technique give rise to giant cell formation. These macrophage polykaryons are believed to be formed by fusion of macrophages derived from monocytes (Al-Sumidaie 1986, 10 Journal of Immunological Methods 91, pages 237-242).

It has been suggested that giant cell formation most likely results from virally mediated cell fusion. Possible explanations for the giant cell formation from monocytes are:-

15 (1) A defect in cellular immunity, resulting from viral infection of monocytes, may produce an increase in tumour incidence as a result of failure to eliminate abnormal cells arising by spontaneous mutation.

20 (2) All the cells in the body are infected by a virus which expresses itself in monocytes in the ability to form giant cells and in decreased migration and phagocytosis, but expresses itself in breast tissue as a carcinogenicis. (Al-Sumidaie et al. 1986, British 25 Journal Surgery 73, pages 839-842).

A link can therefore be deduced between breast cancer and depressed monocyte functions in patients suffering from breast cancer. The question which has to be answered is whether a retrovirus could be shown 5 to be that link.

It has now been surprisingly found that incubation of monocytes taken from patients with breast cancer, in a culture medium containing dexamethasone, Phorbol myristate acetate or 5' azacytidine for 6 days 10 caused release of particles in the supernatant which showed reverse transcriptase activity and hence indicated a retrovirus to be present. This result was all the more surprising when it is considered that no activity could be detected when a normal incubation 15 period of 18 hours was used and the activity was very low when dexamethasone, Phorbol myristate acetate or 5' azacytidine was omitted from the incubation mixture. This is unlike the case when adrenocorticoids were used to enhance MMTV detection in cultured murine carcinoma 20 cells in which detection could be made within short incubation periods. Furthermore, when 5' azacytidine or Phorbol myristate acetate was added to mouse mammary tumour cell cultures, reverse transcriptase activity doubled compared with the same cell line incubated in 25 the presence of dexamethasone. Conversely, the reverse

transcriptase activity released by mononuclear cells from patients with breast cancer was 3 to 7 times when these cells were incubated in the presence of 5' azacytidine, while the activity increased 60 to 120 times when these cells were incubated in the presence of Phorbol myristate acetate compared with same samples incubated in the presence of dexamethasone.

In accordance with one embodiment of the present invention there is provided a method of forming a retrovirus-containing fraction from monocytes or mononuclear cells containing said virus comprising, preparing a suspension of separated monocytes or mononuclear cells in a culture medium, incubating said culture and separating the culture supernatant from said incubated culture, characterized in that an effective amount of glucocorticoid or of a leukemia or other viral or retroviral inducing drug is added to the suspension before and/or during the incubation of said cultures, and if desired separating a retrovirus-containing fraction from the separated supernatant.

In another embodiment the invention provides a method of detecting the presence of retroviruses in monocytes or mononuclear cells which is characterized by subjecting a culture of said cells to incubation in

the presence of a glucocorticoid hormone or active derivative thereof or of a leukemia or other viral or retroviral inducing drug to form a retrovirus-containing fraction and subjecting the fraction to test procedures for detecting said virus.

5 In another embodiment the present invention provides a method of screening human beings for the presence of retrovirus characterized by subjecting a culture of monocytes or mononuclear cells, taken from 10 the individual to be screened to incubation in a culture in the presence of an amount of a glucocorticoid or of a leukemia or other viral or retroviral inducing agent sufficient when retrovirus is present to give rise in the supernatant to particles 15 containing said retrovirus and subjecting said particles when present to a test procedure which determines the presence of said virus.

In a further embodiment the present invention provides a method of converting a non-detectable form 20 of retrovirus to a detectable form of said virus characterized by subjecting a specimen comprising monocytes or mononuclear cells containing a non-detectable form of said virus to incubation in a culture medium preferably for a period greater than 18 25 hours in the presence of a glucocorticoid or a

leukemia or other viral or retroviral inducing agent to give rise to a fraction containing a detectable form of said virus.

The invention also provides a vehicle for 5 effecting said conversion from a non-detectable form of retrovirus to a detectable form which comprises a culture medium containing an effective amount of glucocorticoid hormone or an active derivative thereof or of a leukemia or other viral or retroviral inducing 10 agent.

The glucocorticoid hormone may be, for example, in the form of the synthetic drug dexamethasone and the leukemia or viral inducing agent may be, for example, tetradecanoyle phorbol acetate, especially Phorbol 15 myristate acetate (TPA), azacytidine.

By way of example only, more specific embodiments of the present invention will now be described:

In accordance with one more specific embodiment especially 5' azacytidine, aminopterin, 8-azaguanine, 20 azaserine, 2-amino-6-mercaptopurine, carboxyethyl-gama-aminobutyric acid, demecolcine, dimethyl sulfoxide, ouabain, polyethyleneglycol, pristane or other viral or retroviral stimulators, preferably for periods of 3 to 60 days of the present 25 invention there is provided a method of forming a

retrovirus-containing fraction from monocytes or mononuclear cells or preferably but not essentially purified monocytes containing said virus comprising preparing a suspension of separated mononuclear cells or purified monocytes in a culture medium, incubating 5 said culture and separating the culture, characterized in that an effective amount of dexamethasone, Phorbol myristate acetate or 5' azacytidine is added to the suspension before and/or during the incubation of said 10 cultures, and if desired separating a retrovirus-containing fraction from the separated supernatant. In a preferred embodiment, said culture medium comprises Eagle's medium supplemented with 10 per cent foetal calf serum, said incubation time is 3 15 to 30 days, preferably 6 days and said effective amount of Phorbol myristate acetate is 330 ng per ml of incubating culture medium. The incubation is preferably carried out at substantially 37 degrees C and in an atmosphere of 5 per cent CO₂ in air. Said 20 retrovirus-containing fraction is separated preferably though not necessarily by filtration means, filtration preferably being carried out with a 220 nm filter. Said filtrate is centrifuged at high speed, preferably at 10,000 G for 5 to 15 minutes, and maintaining a 25 temperature preferably of 18 degrees C and the pellet

being suspended in a suitable medium as required.

In another more specific embodiment the invention provides a method of detecting the presence of retroviruses in monocytes said method comprising incubating said culture cells in the presence of Phorbol myristate acetate (330m ng per ml of incubating medium, 10^{-6} M dexamethasone or 15 μ M of 5' azacytidine as hereinbefore defined, said retrovirus-containing fraction being subjected to detection means. Said detection means preferably comprises a reverse transcriptase assay. For said assay the resuspended high-speeded pellet obtained from the supernatant is disrupted by the addition of a non-ionic detergent. Preferably NP40 (final concentration 0.2% v/v) and dithiothreitol (DTT) (final concentration 50mM) and 15 incubated under suitable conditions, preferably at 20 degrees C for 15 minutes. The reverse transcriptase activity is then measured by a standard assay procedure using the divalent ion Mg^{2+} due to its preferential effect with the human cells. As an alternative an assay procedure using Mn^{2+} may also be used. Thus, said reverse transcriptase activity is assayed by measuring the incorporation of radioactively labelled deoxycytidine triphosphate (dCTP) into acid-precipitable material, dependent on the presence 20 25

of a synthetic RNA template. The reaction mix contains a final volume of 100 μ l, 45 μ l of extract, 5 μ mol "tris"-HCl pH 8.3, 5 μ mol KCl, 2.5 μ mol DDT, 0.6 μ mol MCl_2 , 0.16 μ mol each deoxyadenosine triphosphate (dATP), 5 μ l deoxythymidine triphosphate (dTTP), deoxyguanosine triphosphate (dGTP), 0.05 μ mol dCTP, 5 μ Ci (α 32 p) dCTP (3000 Ci/mmol), 0.5 μ g oligodeoxycytidylic acid (oligo d (p^c)₈), 0.5 μ g polyguanylic acid. The reaction is incubated at 37 degrees C for 1 hour. The reaction is stopped by the addition of 0.4 ml of 10 percent (w/v) trichloroacetic acid (TCA) and 25 μ g of calf thymus DNA. The DNA was precipitated overnight at - 20 degrees C. The DNA was sonicated at periods between 5 to 1 minute preferably 15 30 seconds. The precipitated radioactive DNA is collected by filtration onto a GF/C glass-fibre filter, and washed with 30 ml of 5 percent (w/v) TCA, the radioactivity on the filter was measured by means of a scintillation counter.

Whilst detection has been described by the means of the foregoing example, alternative detection means, such as negative staining electron microscopy of the pellet present in the supernatant of incubated monocytes or mononuclear cells; electron microscopic examination of incubated monocytes or mononuclear

cells; histoimmunoassay; immunocytochemical assay, particularly immunogold or immunosilver staining of incubated or fresh monocytes or mononuclear cells; giant cell formation by monocytes or antigen antibody reaction, for example, peroxidase antiperoxidase, alkaline phosphatase-antialkaline phosphatase, Avidin-biotin or immunosorbent assays (ELISA). The antibody could be raised as polyclonal or monoclonal using, for example, rabbits, horses, goats, sheep, 10 swine or mice.

In yet another more specific embodiment of the present invention, there is provided a method of screening human beings for the presence of retrovirus characterized by subjecting said culture of monocytes taken from said individual to be screened as hereinbefore defined and subjecting said centrifuged filtrate to a screening means to determine the presence 15 of said retrovirus.

In a further more specific embodiment the present 20 invention provides a method of converting a non-detectable form of retrovirus to a detectable form of said virus by subjecting monocytes containing a non-detectable form of said virus to incubation in a culture medium, preferably for more than 18 hours, 25 containing Phorbol myristate acetate, preferably at a

concentration of 330 ng per ml of incubating culture medium, dexamethasone, preferably at a concentration up to 10^{-6} M, or 5' azacytidine, preferably at a concentration of 15 μ M, to give rise to a fraction containing a detectable form of said virus.

5 In another embodiment the invention provides a vehicle for effecting said conversion from a non-detectable form of retrovirus to a detectable form which comprises a culture medium containing Phorbol myristate acetate preferably at a concentration of 330 ng per ml incubating culture medium, dexamethasone, preferably at a concentration of 10^{-6} M of 5' azacytidine, preferably at a concentration of 15 μ M.

10 The invention is not restricted to the details of the foregoing embodiment since the virus is not necessarily located only in monocytes. Furthermore, other hormones may be used to initiate or enhance replication of the virus by expression at the level of transcription.

15 By way of a more specific embodiment of the present invention the blood collected for monocytes preparation can be treated with sodium or lithium heparin without interfering with the method for preparing mononuclear cells. The blood can further be 20 kept, preferably in polycarbonate tubes, for a period 25

of up to 8 hours at around 4 degrees C before undergoing mononuclear cell separation.

The mononuclear cells can be further stored at around 4 degrees C for up to 24 hours when in a 5 suitable buffered solution.

Furthermore said culture medium for incubation of said monocytes or mononuclear cells can be prepared with or without antibiotics. Said media containing a suitable feed in particular a good protein source, 10 preferably foetal calf serum at a concentration of between 5 and 20 preferably 7.5 to 12.5 per cent more preferably 10 per cent. The pH of said medium being kept within the range pH 6.8 to 8 preferably to 7.6 especially 7.4. Said culture medium being supplied with air containing CO₂ at a concentration of 4-8 percent preferably 5 percent. Said culture being maintained at a temperature of between 34 and 40 15 preferably between 36 and 40, especially 37.3 degrees C. The Phorbol myristate acetate, can be added to said medium at any period during the incubation procedure but must be added at least 2 days before the reverse transcriptase assay for best results. The period of incubation being maintained for up to 30 days 20 preferably 6 days. Similar factors apply when 5' azacytidine or dexamethasone are used. 25

The preferred concentrations for use of said chemicals being in the range 100 to 600 ng per ml of culture medium preferably 330 ng for Phorbol myristate acetate and 10^{-5} M to 10^{-7} M preferably 10^{-6} M for 5 dexamethasone and in the range 5 μ M to 50 μ M, preferably 10 μ M to 20 μ M, especially 15 μ M for 5' azacytidine.

10 The monocytes or mononuclear cells can be separated from the said medium by a slow speed centrifuge in the range 600 to 800 xg for 10 to 20 minutes at a temperature of between 4 degrees and 20 degrees C. The monocytes or the mononuclear cells can then be resuspended in fresh medium and procedures repeated as necessary.

15 In accordance with a more specific embodiment of forming said retrovirus containing supernatant, said supernatant is separated from the monocytes or the mononuclear cells by either filtration through a suitable membrane with a pore size which allows the 20 virus to pass through, yet retains the monocytes or the mononuclear cells, said filter preferably being 220 nm or by centrifugation at 600-800 xg for 10 to 20 minutes.

25 Said supernatant containing said viral particles may then undergo a high-speed centrifugation to

precipitate said viral particles, said centrifugation being carried out at 8,000 to 120,000 xg preferably 12,000 xg at 4 degrees C to 20 degrees C for 5 to 120 minutes, preferably for 12 minutes.

5 In another more specific embodiment the detection means provided by assaying reverse transcriptase is dependent upon the viability of the monocytes or the mononuclear cells, which can be determined on an aliquot of the sample after incubation with the Phorbol 10 myristate acetate, dexamethasone or 5' azacytidine.

Furthermore, the detection means proved equally effective in determining retrovirus activity in either male or female subjects with breast cancer.

15 In yet a further specific embodiment of the present invention there is provided a method of choosing an efective treatment for a particular breast cancer.

20 The present invention also provides in a specific embodiment a method of detecting the effect of surgery, such as mastectomy with or without lymph node clearance, Halsted radical mastectomy, modified radical mastectomy, quadrantectomy or lumpectomy with or without lymph node clearance on the retrovirus present in the mononuclear cells or monocytes from an 25 individual having breast cancer.

The method of the invention may be used as a tool for selecting an effective treatment or treatments for a breast cancer before actually administering that treatment or treatments. The method of the invention 5 may also be used to monitor the effectiveness of a treatment or treatments on a patient already undergoing such treatment or treatments. These treatments may be single or combined and may include the following:

(1) Surgical treatment, such as Halsted radical mastectomy, modified radical mastectomy, quadrantectomy or lumpectomy, optionally with radiotherapy, Cytotoxic drugs, hormonal therapy, viral or retroviral inhibitors or a combination of all.

(2) Radiotherapy, and in particular, though not exclusively, radiotherapy in locally advanced breast cancer or radiotherapy in metastatic breast cancer, or 15 optionally with cytotoxic drugs, hormonal therapy or viral or retroviral inhibitors.

(3) Cytotoxic drugs (single or combined), for 20 example L-phenylalanine mustards, 5-fluorouracil, adriamylin, Cyclophosphamide, methotrexate, vincristine and epirubicin, optionally with hormonal therapy or viral or retroviral inhibitors.

(4) hormonal therapy, such as with tamoxifen or a 25 derivative thereof, progesterone, progestines,

medroxyprogesterone, norethisterone, megestrol, androgens, aminoglutethimide, oestrogen, cortecosteroids, prolactin or antiprolactin agents, optionally with viral or retroviral inhibitors.

5 (5) viral or retroviral inhibitors, for example interferons, lymphokines, azidothymidine, N-methylisatin-beta-4': 4-diethylthiosemicarbazone, 3'-azido, 3'-amino, 2', 3'-unsaturated, and 2', 10 3'-dideoxy analogues of pyrimidine deoxyribonucleosides, 2-deoxyglucose, tunicamycin or their derivatives, optionally with other forms of 15 treatments as above in 1 to 4.

Another use of the invention may be to detect the effect of drugs such as viral, antiviral, hormonal, and 15 cytotoxic drugs for treatment of or prophylaxis for carcinomas by incubating such drug with the monocytes or mononuclear cells suspended in a suitable medium during culture of or during the assay for the retrovirus present in these cells, for example, by 20 incubating the monocytes or mononuclear cells in the presence of the viral or retroviral stimulator.

The embodiments described hereinbefore are further illustrated by the following examples.

PREPARATIVE EXAMPLES

Preparative Example 1

Blood Collection

Peripheral venous blood (40 ml) was collected from each subject in plastics tubes containing 10 IU preservative free heparin per ml. The blood was taken 5 from the patients when they first presented in clinic with breast lumps. Full biochemical (sequential multichannel analyser with computer, SMAC) and haematological analysis revealed no abnormalities in 10 either patients or controls.

Mononuclear Cell Separation and Monocyte Purification:

Mononuclear cells were separated from blood by centrifugation over Ficoll-Hypaque, 1.077 gm/ml density (Boyum 1968, Scandinavian Journal of Clinical and 15 Laboratory Investigation 21 (suppl. 97), pages 77-89) and washed 3 times with ice cold buffered salt solution (BSS) prepared from 8.0 gm NaCl, 0.2 g KCl, 1.15g Na₂HPO₄, 0.2 g KH₂PO₄ and 0.2 g glucose in 1 litre sterile distilled water.

20 Monocytes were purified on a discontinuous

density gradient of Percoll. Stock Percoll was prepared by mixing 9 parts of Percoll density 1.13 g/ml with 1 part of 10 times strength Eagle's medium. The 3 densities of Percoll were prepared as shown in Table I. Up to 40×10^6 mononuclear cells were suspended in 2 ml of Percoll density 1.074 g/ml and placed in a 10 ml polycarbonate centrifuge tube (Nunc, Denmark). Two millilitres of Percoll density 1.066 g/ml were gently layered over the first layer and another 2 ml of Percoll density 1.057 g/ml gently layered on top of the latter. The tube was centrifuged at 2200 $\times g$ for 90 minutes at room temperature. After centrifugation, 3 bands of cells could be identified. The monocyte rich band was found at the interface of the 1.057 g/ml and the 1.066 g/ml density gradient of Percoll. This band was carefully removed and washed 3 times with ice cold BSS, and a sample of cells taken for non-specific esterase staining, total and viability counts. The total number of cells was adjusted to 25×10^6 cells/ml in Eagle's medium pH 7.1.

Cells were counted in a haemocytometer, and viability determined by trypan blue dye exclusion. Non-specific esterase staining used was by the method Yam et al., 1971 American Journal of Pathology, 55

pages 283-290.

All cell manipulations were carried out using sterile materials and solutions in a laminar flow hood.

TABLE I

5 PREPARATION OF THE THREE ISO-OSOMOLAR ($\text{osM} = 310$)
 mosmol/1) DENSITIES OF PERCOLL USED IN THE
 DISCONTINUOUS DENSITY GRADIENT

		Stock Solution (ml)	Eagle's medium (ml)
10	Percoll s.g. 1.057 g/ml	42.4	57.6
	Percoll s.g. 1/066 g/ml	50.00	50.00
	Percoll s.g. 1.074 g/ml	56.65	43.35

PREPARATION OF CELL-FREE CULTURE MEDIUM

15 The monocytes from patients and controls were suspended in Eagle's medium supplemented with 10 percent foetal calf serum and Phorbol myristate acetate (300 ng per ml of culture medium). After 6 days incubation at 37 degrees C in 5 percent CO_2 in air, in a humidified incubator, the supernatant was filtered

using a 220 nm filter. The filtrates were centrifuged at 12,000 xg for 12 minutes at 18 degrees C. For reverse transcriptase assay the pellets were suspended in 1 ml of T.N.E. medium (10 mM "tris"-HCl pH 8.3, 150 nM NaCl, 2 nM EDTA). For stimulation of giant cell formation among control monocytes or for electron microscopy the pellets were suspended in Eagle's medium (1 ml). For negative-staining electron microscopy the suspension was fixed with 0.25 percent glutaraldehyde-cacodylate, mixed with phosphotungstic acid (2 percent) and examined using a Philips 301 electron microscope.

REVERSE TRANSCRIPTASE ASSAY:

The resuspended high speed pellets obtained from the cell-free culture medium of incubated mononuclear cells or monocytes or from mouse mammary tumour cells were disrupted by the addition of the nonionic detergent NP40 (final concentration 0.2 percent v/v) and dithiothreitol (final concentration 50 nM) and incubating at 20 degrees C for 15 minutes.

Reverse transcriptase activity was assayed by measuring the incorporation of radioactively labelled dCTP into acid-precipitable material, dependent on the

presence of a synthetic RNA template. The reaction mix contained, in a final volume of 100 μ l, 45 μ l of extract, 5 μ mol "tris"-HCl pH 8.3, 5 μ mol KC1, 2.5 μ mol DTT, 0.6 μ mol MgCl₂, 0.16 μ mol each dATP, dTTP, dGTP, 5 μ mol dCTP, 5 μ Ci (α ³² p) dCTP (3000 Ci/mmol), 0.5 μ g oligodeoxycytidylic acid (oligo d(p^c)₈), 0.5 μ g polyguanylic acid. The reaction was incubated at 37 degrees C for 1 hour. The reaction was stopped by the addition of 0.4 ml of 10 percent (w/v) trichloroacetic acid (TCA) and 25 μ g of calf thymus DNA. The DNA was precipitated overnight at -20 degrees C. The precipitated radioactivity was collected by filtration onto a GF/C glass-fibre filter and washed with 30 ml of 5 percent (w/v) TCA. The radioactivity on the filter was measured by scintillation counting.

15 All assays were performed in triplicate.

Preparative Example 2

In this, the procedure is as for preparative Example 1 except that in the preparation of the cell-free culture medium in which monocytes or mononuclear cells had been incubated there is the following difference.

20 The monocytes or mononuclear cells from patients

and controls were suspended in Eagle's medium supplemented with 10 percent foetal calf serum and Phorbol myristate acetate at a concentration of 330 ng per ml of culture medium or 5' azacytidine at 15 μ M.

5 After 6 days incubation at 37 degrees C in 5% CO₂ in air, in a humidified incubator, the supernatant was filtered using a 200 nm filter. The filtrates were centrifuged at 12,000 xg for 12 minutes at 18 degrees C. For reverse transcriptase assay the pellets were suspended in 1 ml of T.N.E. medium (10 nM "tris"-HCl pH 10 8.3, 150 nM NaCl, 2 mM EDTA). For stimulation of giant cell formation among control monocytes or for electron microscopy the pellets were suspended in Eagle's medium (1 ml). For negative-staining electron microscopy the 15 suspension was fixed with glutaraldehyde-cacodylate, mixed with phosphotungstic acid (2 percent) and examined using a Philips 301 electron microscope.

SUCROSE GRADIENT

A high speed pellet was prepared from the 20 cell-free culture medium of incubated monocytes from patients with breast cancer as described previously. The pellets were resuspended in 100 μ l of T.N.E. medium and layered on discontinuous densities of sucrose 20,

30, 40 and 60 percent in T.N.E. gradient and centrifuged (preferably but not necessarily in Beckman SW65 rotor) at 120,000 xg for 16 hours at 4 degrees C. Fractions (250 ml) were collected by piercing the bottom of the tube, diluted in T.N.E. centrifuged at 12,000 xg for 12 minutes and the pellets were assayed for reverse transcriptase. The density of the sucrose was determined using a refractometer.

Example 3 shows the reverse transcriptase activity in the cell-free culture medium in which monocytes or mononuclear cells from patients with breast cancer had been indubated was associated with a particle having a buoyant density between 1.165 and 1.18 g/ml on a sucrose density gradient.

15 e.g. 3

	Fraction number	g/ml sucrose	Reverse transcriptase
		density	activity (cpm)
	1	1.29	20,000
	2	1.28	1,000
20	3	1.26	2,000
	4	1.23	500
	5	1.21	2,000
	6	1.19	500

7	1.18	40,000
8	1.165	37,000
9	1.155	4,000
10	1.145	4,500
5	11	200
	12	300
	13	300
	14	600
	15	40

10 Example 4 shows the results obtained using the preparative method 1 hereinbefore described in which the chemical dexamethasone was used in the culture medium containing monocytes or mononuclear cells. In which the monocytes or the mononuclear cells were obtained from breast cancer patients and age matched controls respectively.

	No of subjects tested	Reverse Trans- criptase	Giant Cell formation	Examination for viral particles
20	using prepara- tion	or retro- virus	containing	using Electron Microscope
	example 1	fraction		

e.g. 4

isolated
fraction
from cultured
monocytes
5 of breast
cancer

patients	28	27+'ve	28+'ve	28+'ve
----------	----	--------	--------	--------

isolated
fraction
10 from cultured
monocytes or
mononuclear
cells of
age matched
15 controls 18 2+'ve 2+'ve 2+'ve

Example 5 shows the importance of dexamethasone on the reverse transcriptase activity in a patient with breast cancer.

Sample	Reverse transcriptase activity
Isolated fraction prepared from	2770 cpm (6.1 picomoles dCTP)

monocytes or incorporated)
 mononuclear cells
 of a breast cancer
 patient treated
 5 with dexamethasone

Isolated fraction 620 cpm
 prepared from (1.4 picomoles dCTP
 monocytes, of a incorporated)
 breast cancer
 10 patient, not treated
 with dexamethasone

Example 6 shows comparisons of reverse
 transcriptase activity on isolated fractions, of age
 matched controls, treated with and without
 15 dexamethasone respectively.

e.g. 6

	Sample	Reverse transcriptase Activity
20	Isolated fraction of control subject, with dexamethasone	228 cpm (0.5 picomoles dCTP incorporated)

Isolated fraction 135 cpm
 of control subject, (0.3 picomoles dCTP
 without dexamethasone incorporated)

Example 7 shows the effect of dexamethasone in
 5 cultures of monocytes or mononuclear cells, 5' azacytidine in cultures of monocytes or mononuclear cells and Phorbol myristate acetate in cultures of monocytes or mononuclear cells in terms of reverse transcriptase activity in a patient with breast cancer
 10 using Mg⁺² in the assay.

R.T. Activity

Phorbol myristate acetate treated isolated fraction	112761 cpm (248 picomoles dCTP incorporated)
Azacytidine treated isolated fraction	7718 cpm (17 picomoles dCTP incorporated)
Dexamethasone treated isolated fraction	2410 cpm (5.3 picomoles dCTP incorporated)

Isolated fraction from 510 cpm
 culture containing no (1.1 picomoles dCTP
 dexamethasone, 5' incorporated)
 azacytidine, or
 5 Phorbol myristate
 acetate

Example 8 shows the effect of Mn^{2+} or Mg^{2+} when
 used in the reverse transcriptase assay with a patient
 with a breast cancer using Phorbol myristate acetate as
 10 retroviral stimulator.

Sample	R.T. Activity
Mg^{2+}	42710 cpm (94 picomoles dCTP incorporated)
15 Mn^{2+}	= 18260 cpm (40 picomoles dCTP incorporated)

Example 9 shows the effect of the period of
 incubation on reverse transcriptase activity in the
 20 isolated fraction from a patient with breast cancer and

a control subject using Phorbol myristate acetate as viral stimulator, and Mg^{2+} in the assay.

	Time	R.T. Activity
1. Breast cancer		
5 patient	at 8 days	32590 cpm (71.6 picomoles dCTP incorporated)
10	at 15 days	35830 cpm (78.7 picomoles dCTP incorporated)
2. Control subjects		
15	at 10 days	250 cpm (0.5 picomoles dCTP incorporated)
	at 16 days	310 cpm (0.7 picomoles dCTP incorporated)

Example 10 shows the effect of the time of

centrifugation of the cell-free culture medium in which monocytes or mononuclear cells were incubated on reverse transcriptase activity in a patient with breast cancer.

	Time	R.T. Activity
5	5 minutes	55480 cpm (122 picomoles dCTP incorporated)
10	10 minutes	71470 cpm (157 picomoles dCTP incorporated)
15	12 minutes	75460 cpm (166 picomoles dCTP incorporated)
20	15 minutes	75950 cpm (167 picomoles dCTP incorporated)
	60 minutes	77010 cpm (169 picomoles dCTP incorporated)

Example 11 shows the effect of mastectomy on reverse transcriptase activity in patients with breast

cancer.

Reverse transcriptase activity is expressed in cpm per 45 μ l of sample and picomoles of dCTP incorporated per 45 μ l of sample.

	Patients before operation	3 months after operation
5		
1	50927 cpm (134 picomoles)	54712 cpm (120 picomoles)
2	32616 cpm (72 picomoles)	31792 cpm (70 picomoles)
10		
3	50148 cpm (110 picomoles)	52744 cpm (116 picomoles)
4	27547 cpm (61 picomoles)	24080 cpm (53 picomoles)
15		
5	47175 cpm (104 picomoles)	51684 cpm (114 picomoles)
6	21774 cpm (48 picomoles)	19524 cpm (43 picomoles)

Example 12 shows the effect of mastectomy with lymph node clearance on reverse transcriptase activity in patients with breast cancer. Reverse transcriptase is expressed in cpm per 45 μ l of sample and picomoles of dCTP incorporated per 45 μ l of sample.

	Patients before operation	3 months after operation
1	27154 cpm (60 picomoles)	25517 cpm (56 picomoles)
5	2 18178 cpm (40 picomoles)	16211 cpm (36 picomoles)
10	3 40114 cpm (88 picomoles)	42898 cpm (94 picomoles)
	4 25296 cpm (56 picomoles)	22686 cpm (50 picomoles)

Example 13 shows the effect of lumpectomy with lymph node clearance followed by a course of radiotherapy to the chest wall and the axillary region. Reverse transcriptase activity is expressed as cpm per 15 45 μ l of sample or picomoles of dCTP incorporated per 45 μ l of sample.

	Patients before treatment	3 months after treatment
1	22862 cpm (50 picomoles)	10195 cpm (22 picomoles)
20	2 16932 cpm (37 picomoles)	7912 cpm (17 picomoles)

3	45660 cpm (100 picomoles)	38976 cpm (86 picomoles)
4	35734 cpm (79 picomoles)	9788 (22 picomoles)

5 Example 14 shows the effect of tamoxifen (taken by patients with breast cancer) on reverse transcriptase activity. Reverse transcriptase activity is expressed as cpm per 45 μ l of sample or picomoles of dCTP incorporated per 45 μ l of sample.

10	Patients before treatment	3 months after treatment
1	50799 cpm (112 picomoles)	2457 cpm (5 picomoles)
2	18162 cpm (40 picomoles)	3146 cpm (7 picomoles)
15	3 27005 cpm (59 picomoles)	23125 cpm (51 picomoles)
	4 22972 cpm (50 picomoles)	4492 cpm (10 picomoles)

20 Example 15 shows the effect of different concentrations of tamoxifen on reverse transcriptase activity. The drug was added during the incubation of

monocytes or mononuclear cells from a patient with breast cancer. Reverse transcriptase activity is expressed in cpm 45 μ l of sample and picomoles of dCTP incorporated per 45 μ l of sample.

5

Reverse transcriptase
activity

10

No tamoxifen	32635 cpm (72 picomoles)
150 ng per ml tamoxifen	21669 cpm (48 picomoles)
300 ng per ml tamoxifen	7895 cpm (17 picomoles)
600 ng per ml tamoxifen	743 cpm (1.6 picomoles)

15

Example 16 shows the effect of different concentrations of medroxyprogesterone acetate on reverse transcriptase activity. The drug was added during the incubation of monocytes or mononuclear cells from a patient with breast cancer. Reverse transcriptase activity is expressed in cpm per 45 μ l of sample and picomoles of dCTP incorporated per 45 μ l of sample.

20

Reverse transcriptase activity		
	No medroxyprogesterone	25016 cpm (55 picomoles)
5	100 ng per ml medroxyprogesterone	12995 cpm (29 picomoles)
	200 ng per ml medroxyprogesterone	2479 cpm (5 picomoles)
10	400 ng per ml medroxyprogesterone	1078 cpm (2 picomoles)

Example 17 shows the effect of 5-fluorouracil on reverse transcriptase activity. The drug was added during the incubation of monocytes or mononuclear cells from a patient with breast cancer. Reverse transcriptase activity is expressed as cpm per 45 μ l of sample and picomoles of dCTP incorporated per 45 μ l of sample.

Reverse transcriptase activity		
20	No drug	22010 cpm (48 picomoles)
	with 5-fluorouracil	3408 cpm (7 picomoles)

Example 18 shows the effect of aminoglutethimide on reverse transcriptase activity. The drug was added during the incubation of monocytes or mononuclear cells from a patient with breast cancer. Reverse transcriptase activity is expressed in cpm per 45 μ l of sample and picmoles of dCTP incorporated per 45 μ l of sample.

		Reverse transcriptase activity
10	No drug	32715 cpm (72 picmoles)
	with aminoglutethimide	5423 cpm (12 picmoles)

Example 19 shows the effect of tamoxifen on reverse transcriptase activity. The drug was added to the incubated monocytes or mononuclear cells from patients with breast cancer. Reverse transcriptase activity is expressed in cpm per 45 μ l of sample and picmoles of dCTP incorporated per 45 μ l of sample.

20	Sample	without tamoxifen	with tamoxifen
	1	44546 cpm	4220 cpm

	(98 picomoles)	(9 picomoles)
2	25792 cpm	6217 cpm
	(57 picomoles)	(14 picomoles)
3	38117 cpm	835 cpm
5	(84 picomoles)	(1.8 picomoles)
4	20170 cpm	18189 cpm
	(44 picomoles)	(40 picomoles)

Example 20 shows the effect of tamoxifen on reverse transcriptase activity. The drug was added 10 during the reverse transcriptase assay to the pellet from the supernatant of incubated monocytes or mononuclear cells from a patient with breast cancer. Reverse transcriptase is expressed in cpm per 45 μ l of sample and picomoles of dCTP incorporated per 45 μ l of sample.

	Reverse transcriptase
	activity
	without tamoxifen
	47332 cpm
	(104 picomoles)
20	with tamoxifen
	489 cpm
	(1.1. picomoles)

CLAIMS

1. A method of forming a retrovirus-containing fraction from monocytes or mononuclear cells containing said virus comprising, preparing a suspension of separated monocytes or mononuclear cells in a culture medium, incubating said culture and separating the culture supernatant from said incubated culture, wherein an effective amount of a glucocorticoid or of a leukemia or other viral or retroviral inducing drug is added to the suspension before and/or during the incubation of said cultures.
2. A method as claimed in claim 1 comprising the step of separating a retrovirus containing fraction from the separated supernatant.
3. A method as claimed in claim 1 or 2, wherein the glucocorticoid hormone is in the form of dexamethasone.
4. A method as claimed in claim 1, 2 or 3, wherein the leukemia or viral or retroviral inducing agent is Phorbol myristate acetate or 5' azacytidine.
5. A method as claimed in claim 4, wherein the culture medium comprises Eagle's medium supplemented with 10% foetal calf serum, said incubation time is 3 to 30 days and said effective amount of Phorbol

myristate acetate is 330 ng per ml of incubating culture medium.

6. A method as claimed in claim 5, wherein the incubation is carried out at substantially 37 degrees C and in an atmosphere of 5% CO₂ in air.

7. A method of detecting the presence of retroviruses in monocytes or mononuclear cells comprising subjecting a culture of said cells to incubation in the presence of a glucocorticoid hormone or active derivative thereof or of a leukemia or other viral or retroviral inducing drug to form a retrovirus containing fraction and subjecting the fraction to test procedures for detecting said virus.

8. A method as claimed in claim 7, wherein the glucocorticoid hormone is in the form of dexamethasone.

9. A method as claimed in claim 7 or 8, wherein the leukemia or viral or retroviral inducing agent is Phorbol myristate acetate or 5' azacytidine.

10. A method as claimed in claim 7, 8 or 9 comprising incubating said culture cells in the presence of Phorbol myristate acetate (330 ng per ml of incubating medium) 10⁻⁶ M dexamethasone or a 15 μ M of 5' azacytidine, said retrovirus containing fraction being subjected to detection means.

25 11. A method as claimed in any one of claims 7 to 10

comprising the step of isolating said fraction prior to testing.

12. A method as claimed in any one of claims 7 to 11, wherein said detection means comprises a reverse 5 transcriptase assay.

13. A method as claimed in any one of claims 7 to 11, wherein the detection means comprises negative staining electron microscopy.

14. A method as claimed in any one of claims 7 to 11, 10 wherein the detection means comprises giant cell formation.

15. A method as claimed in any one of claims 7 to 11, wherein the detection means comprises antibody reaction.

15 16. A method of screening human beings for the presence of retrovirus as comprising subjecting a culture of monocytes or mononuclear cells, taken from the individual to be screened, to incubation in a culture in the presence of an amount of a 20 glucocorticoid or of a leukemia or other viral or retroviral inducing agent sufficient when retrovirus is present to give rise in the supernatant to particles containing said retrovirus and subjecting said particles when present to a test procedure which 25 determines the presence of said virus.

17. A method as claimed in claim 14 comprising subjecting said culture of monocytes taken from said individual to be screened and subjecting said centrifuged filtrate to a screening means to determine the presence of said retrovirus.

18. A method as claimed in claim 16 or 17, wherein the glucocorticoid is in the form of dexamethasone.

19. A method as claimed in claim 16, 17 or 18, wherein the leukemia or viral or retroviral inducing drug is Phorbol myristate acetate or 5' azacytidine.

20. A method of converting a non-detectable form of retrovirus to a detectable form of said virus characterised by subjecting a specimen comprising monocytes or mononuclear cells containing a non-detectable form of said virus to incubation in a culture medium in the presence of a glucocorticoid or a leukemia or other viral or retroviral inducing agent to give rise to a fraction containing a detectable form of said virus.

21. A method as claimed in claim 20, wherein the glucocorticoid is in the form of dexamethasone.

22. A method as claimed in claim 20 or 21, wherein the leukemia or viral or retroviral inducing agent is Phorbol myristate acetate or 5' azacytidine.

23. A vehicle for effecting conversion of a

non-detectable form of retrovirus to a detectable form which comprises a culture medium containing an effective amount of glucocorticoid hormone or an active derivative thereof or of a leukemia or other viral or retroviral inducing agent.

5 24. A vehicle as claimed in claim 23, wherein the glucocorticoid is in the form of dexamethasone.

25. A vehicle as claimed in claim 23 or 24, wherein the leukemia or viral or retroviral inducing agent is 10 Phorbol myristate or 5' azacytidine.

26. A method of detecting the effect of a drug treatment for prophylaxis for a carcinoma comprising forming a retrovirus-containing fraction from monocytes or mononuclear cells containing a virus by a method as 15 claimed in any one of claims 1 to 6 in the presence of said drug.

27. A method as claimed in claim 1 and substantially as hereinbefore described with reference to any of the foregoing Examples.

20 28. A vehicle as claimed in claim 23 and substantially as hereinbefore described with reference to any of the foregoing Examples.